Clinical Research Directory

Inclusion Criteria: * Men and women with non-Hunner and Hunner lesion disease * Meeting AUA definition of BPS: An unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder associated with lower urinary tract symptoms of greater than 6 weeks duration in the absence of infection or other identifiable cause. * Stable treatment for 1 month * 7-day maximum of pain scores at least 4/10 on the numerical rating scale of pain in the bladder/pelvic area. Urinary frequency 8 or higher while awake. Nocturia 2 or higher. BPIC-SS 19. * Agreement to not take opioids through the duration of the trial Exclusion Criteria: * Substance Use Disorder Diagnosis including Opioid Use Disorder Diagnosis * Known allergy to naltrexone or naloxone * Participation in another clinical trial * Current or planned pregnancy, or breastfeeding * Chronic pain in another location of the body that is more severe than that related to BPS. * Any intravesical instillation in last 8 weeks * If on Elmiron, stable dose for last 3 months * If on amitriptyline, stable dose for last 3 months * Any botox within last 6 months * Treatment for Hunners in the last 6 months * Any new Interstim settings within last 3 months * Any new pelvic floor physical therapy in last 12 weeks * Any change in or new OTC meds over last 2 months. * Any pain interventions in the preceding 6 weeks (epidural steroid injection, sympathetic block, peripheral nerve block, lumbar medial branch blocks) * Opioids chronically for IC/BPS in the past unless have been off for 1 year * Recent short-term (within one week of enrollment) opioid use for flairs * No documented cystoscopy in the last 5 years